1. Introduction {#sec1}
===============

Primary immunodeficiencies are usually due to effector T (Teff) cell impairment and manifest with defective immune responses to pathogens. However, autoimmune manifestations are often present or can even prevail over recurrent infections when the genetic defect affects regulatory T (Treg) cells, which are the major players in maintaining peripheral tolerance [@bib1]. This cell subset is impaired in Immune dysregulation, Polyendocrinopathy, Enteropathy X-linked (IPEX) syndrome, a disease caused by mutations in forkhead box p3 (*FOXP3)* gene, the master switch for the function of Treg cells [@bib2]. Affected males show life threatening autoimmune manifestations, including severe neonatal enteropathy and eczematous dermatitis, frequently associated with type 1 diabetes mellitus (T1DM) and elevated IgE serum levels [@bib3; @bib4; @bib5].

Notably, in about one third of patients, with clinical symptoms closely resembling IPEX syndrome, *FOXP3* is not mutated. These patients are here referred to as IPEX-like [@bib6; @bib7; @bib8; @bib9; @bib10]. Most frequently, the underlying genetic defect leading to IPEX-like syndrome, if present, remains unknown, thus limiting both diagnosis and therapeutic strategies. Phenotypic manifestations similar to those reported for scurfy mice, the natural *foxp3* mutants, have been found also in mice with genetic defects affecting different molecules involved in Treg cells signalling and function, such as IL-2Rα, IL-2, CTLA-4 and STAT5 [@bib11; @bib12; @bib13; @bib14]. In humans, a small number of patients with causative mutations in *CD25* [@bib7; @bib15] or *STAT5b* [@bib16; @bib17; @bib18; @bib19] have been reported and most likely these genetic defects cannot account for the majority of IPEX-like cases.

While in IPEX patients Treg cells, although present, are functionally impaired [@bib4; @bib8; @bib20; @bib21], the contribution of an altered Treg cell compartment in the pathogenesis of IPEX-like syndromes remains elusive. Reduced proportion of peripheral *FOXP3* expressing T cells, as determined by flow cytometric analysis, and their reduced inhibitory activity have been recently reported in two IPEX-like patients under immune suppressive treatment [@bib8], whereas, in another work describing a single IPEX-like patient, a low FOXP3^+^ cell amount at flow cytometric analysis but preserved suppressive function was shown [@bib9]. Indeed, peripheral Treg cell detection and quantification in humans has been so far limited by the fact that the main markers for their identification, CD25 and FOXP3, are also expressed by activated Teff cells [@bib2; @bib22; @bib23], which can be increased in inflammatory conditions [@bib22; @bib24], typically occurring in autoimmune diseases. Also, the use of CD127 as additional marker to discriminate Treg cells from activated Teff cells does not allow precise definition of the Treg cell subset by phenotypic analysis, since Teff cells down-regulate CD127 upon activation [@bib24]. Recently, a highly conserved CpG enriched element, located in the 5′ untranslated region (5′UTR) of *FOXP3* has been identified as the Treg cell-specific-demethylated-region (TSDR), since it is constantly demethylated exclusively in Treg cells [@bib25]. Demethylation of the TSDR is associated with high and stable expression of *FOXP3* [@bib26; @bib27; @bib28] and quantification of the cells carrying demethylated TSDR allows to measure the peripheral proportion of *bona fide* Treg cells vs Teff cells, that maintain a fully methylated TSDR [@bib25; @bib29]. The reliability of this method for the detection of Treg cells in peripheral blood and tissues for clinical purposes has already been demonstrated in cancer patients [@bib29; @bib30].

In this study we quantified Treg cells in the peripheral blood of IPEX-like patients by analysing the demethylation status of the TSDR. In parallel, we evaluated the amount of CD3^+^ T cells by an approach analogous to the TSDR analysis using a specifically demethylated area in the intergenic regions of the *CD3δ* and *CD3γ* genes, a region we here refer to as "T-lymphocyte-specific-demethylated-region" (TLSDR) [@bib30]. Using these methods, we were able to evaluate the relative proportion of peripheral Treg within the total T cells in these patients. Our findings show a quantitative defect in the Treg cell compartment, suggestive of decreased peripheral tolerance in IPEX-like disease. The TSDR demethylation assay showed good specificity and sensitivity, thus candidating this method as a potential tool for quantification of Treg cells in the peripheral blood of patients with immune dysregulation, alternative or complementary to the flow cytometric analysis.

2. Material and methods {#sec2}
=======================

2.1. Patients {#sec2.1}
-------------

Twenty-eight IPEX-like patients (23 males and 5 females) with clinical manifestations resembling IPEX in absence of *FOXP3* mutations, were enrolled for this study (samples collected from 2006 to 2010). Clinical and laboratory parameters allowed exclusion of other monogenic diseases, such as Wiskott Aldrich syndrome, Omenn's syndrome, Hyper IgE syndrome and autoimmune lymphoproliferative syndrome, which should be always considered in the differential diagnosis. Patients presented at least one of the main clinical features of IPEX syndrome, autoimmune enteropathy and/or type 1 diabetes mellitus, associated with one or more of the following: dermatitis, autoimmune thyroiditis, autoimmune haemolytic anemia, autoimmune thrombocytopenia, nephropathy, autoimmune hepatitis, alopecia, hyper IgE (with or without eosinophilia). The age of the patients ranged from 2 months to 38 years (median 5 years). All patients were investigated for the presence of mutations in *FOXP3* and found to be negative. In two patients, a homozygous point mutation of *CD25* was found. The clinical details of 23 patients were available and are summarized in [Table 1](#tbl1){ref-type="table"}. Molecular and clinical details of subjects with IPEX syndrome, included as a control group in [Fig. 3](#fig3){ref-type="fig"}C, are described elsewhere [@bib4] (Pt 3, 9, 11, 12, 14). Twenty-seven patients (non-lymphopenic, both male and female) with well defined autoimmune and autoinflammatory diseases, different from IPEX-like syndrome, have been included as pathologic controls (type 1 diabetes mellitus, *n* = 10; celiac disease, *n* = 9; Crohn's disease, *n* = 8). Forty healthy subjects (HS), aged between 7 months and 32 years (median 9 years), were analysed in parallel. The group of HS was equally distributed among males (*n* = 21) and females (*n* = 19); since no difference was detected in Treg cell percentage, even when normalized to CD3 (not shown), males and females were pooled in a single control group. Peripheral blood was obtained from patients and HS upon informed consent in accordance with the ethical committee of San Raffaele Scientific Institute approval (protocol TIGET02 and TIGET PeriBlood).

2.2. TSDR and TLSDR demethylation analysis {#sec2.2}
------------------------------------------

Genomic DNA for TSDR analysis was isolated using the QIAamp DNA micro kit (Qiagen) from peripheral blood. Bisulfite treatment of genomic DNA, subsequent TSDR- and TLSDR-specific RT-PCR and quantitative evaluation of methylated and unmethylated *FOXP3* and *CD3* DNA were performed as previously described by Wieczorek G. et al. and by Sehouli J. et al., respectively [@bib29; @bib30]. Bisulfite conversion was performed using Qiagen Epitect, following the manufacturer's instructions and the efficiency of conversion was always over 99%, tested according to Lewin et al. [@bib31]. TSDR demethylation analysis evaluates the methylation status of nucleated cells in the peripheral blood, discriminating Treg (TSDR-demethylated) from all non-Treg (TSDR-methylated) cells. Hence, Treg cell amount is expressed as percentage of total nucleated cells of the peripheral blood. Based on TLSDR analysis a patient is considered lymphopenic if CD3-expressing cell percentage on the total nucleated peripheral blood cells is below 14.9% (i.e. the minimum value detected in the cohort of HS included in the present study).

2.3. Flow cytometric analysis {#sec2.3}
-----------------------------

Anti-CD4 and -CD25 mAbs (BD Pharmingen) were used for surface staining. Intracellular staining for FOXP3 (clone 259D, BioLegend) was performed following the manufacturer's instructions. Samples were acquired on BD FACSCanto and analysed with FCS Express Pro Software Version 3 (De Novo Software).

2.4. T cell purification and suppression assays {#sec2.4}
-----------------------------------------------

PBMC were purified over Ficoll-hypaque gradients. Treg cells were isolated either by FACS-sorting of CD4^+^CD25^bright^ T cells or magnetic bead sorting by negative selection of CD4^+^ T cells followed by positive selection of CD25^+^ T cells and were over 90% pure (Miltenyi Biotec). To evaluate Treg cell suppressive activity, PBMC, used as responders, were stained with CFSE (Molecular Probes), following the manufacturer's instructions, and activated in the presence of Treg Inspector coated beads (Miltenyi Biotec). Suppressor cells were added at a variable ratio and the percentage of divided responders after six days of co-culture was calculated by gating on CD4^+^ and/or CD8^+^ cells, as elsewhere described [@bib32]. The suppressive function of Patient \#15 Treg cells was evaluated as follows: allogeneic CD4^+^CD25^−^ T cells selected by magnetic bead sorting were used as responders, activated in the presence of allogeneic antigen presenting cells (APC), irradiated at a dose of 30 Gy and anti-CD3/CD28 mAb, and proliferation was evaluated by ^3^\[H\]-thymidine incorporation after 5 days of co-culture with Treg cells, as elsewhere described [@bib20].

2.5. Statistical analysis {#sec2.5}
-------------------------

Results are presented as median and range. Differences between groups were analysed with the non-parametric Mann--Whitney *U*-test and the relationship between numeric variables by means of Pearson correlation index, as indicated in the text and figure legends. To take into account possible outliers, we estimated a robust regression linear model by means of high breakdown point MM-type estimators.

For the quantitative evaluation of the *FOXP3* methylation-based discrimination of IPEX-like patients vs HS and patients with other disease controls, the area under the "receiver operating characteristics" (ROC) curve (AUC) value and its associated *p*-value were used. This is equivalent to the probability that a randomly selected IPEX-like patient shows a lower percentage of *bona fide* Treg (TSDR-demethylated) cells in peripheral blood than a randomly selected normal control or pathologic control. No discriminative ability corresponds to an AUC of 0.5. A perfect discrimination has an AUC of 1.0. All the analyses were performed with SPSS and R environment. *p*-values lower than 0.05 were considered significant.

3. Results {#sec3}
==========

3.1. Clinical manifestations in IPEX-like patients {#sec3.1}
--------------------------------------------------

As described in [Table 1](#tbl1){ref-type="table"}, the onset of the disease ranged from 1 month (patient \#1) to 19 years (patient \#19), with only 4/23 patients showing a neonatal disease onset (patients \#1, \#14, \#16 and \#22). The most frequent clinical feature in the present cohort of IPEX-like patients was enteropathy, which occurred at variable age. In 20/23 patients the enteropathy involved the small bowel with histological findings including variable degree of villous atrophy and/or a polymorphic inflammatory infiltrate, and usually presenting as watery diarrhoea and weight loss, unresponsive to any dietary restriction, including gluten free diet, elemental enteral diet or total parenteral nutrition. An infectious origin of the enteropathy was excluded in all but three patients (\#1, \#15 and \#22). In two of them early onset CMV infection was associated with CD25 deficiency, which did not allow persistent clearance of the virus. Moreover, in three patients (\#17, \#21 and \#23), there was evidence of colonic inflammation, while in other two cases (\#19 and \#20) an autoimmune atrophic gastritis was found. Remarkably, serological screening for celiac disease and autoimmune enteropathy with detection of anti-transglutaminase and anti-enterocyte auto-antibodies, respectively, resulted negative.

Skin involvement was the second most common sign (16 patients out of 23), although with a wide spectrum of characteristics. In most patients the eczematous lesions were similar to atopic or severe psoriasiform dermatitis and erythrodermia, vitiligo, nodular eritema, bullous pemphigoid and urticaria-like lesions could be also present. Notably, alopecia affected 4 patients (\#1, \#6, \#18, \#20).

T1DM was diagnosed in 7 out of 23 patients and in 6 of them it was associated with enteropathy.

Additional disease features included: i) other autoimmune disorders (in 7/23) such as thyroiditis, cytopenias, hepatitis, cholangitis, ankylosing spondylitis; ii) immunological disorders, such as IgA deficiency (2/23), IgG deficiency (2/23), and slightly to markedly increased levels of IgE (3/23) and eosinophils (1/23); iii) recurrent and severe infections (10/23).

According to the severity of enteropathy and of autoimmune manifestations, immunosuppressive therapy (IS) was administered in 15/23 patients achieving partial control of the clinical picture. Eight patients did not require any systemic IS, they received at least hormone replacement, immunoglobulins, antibiotics and supportive therapy.

Taken together, these findings indicate that patients affected with IPEX-like syndrome can be identified on the basis of the same clinical features used for the diagnosis of IPEX syndrome, including enteropathy, T1DM and skin disease, although IPEX-like may include female patients. The main difference lies in the greater variability of these symptoms in IPEX-like patients, in terms of age at onset and severity. Indeed, the onset can occur in infants or in young adults, intestinal manifestations can involve also the stomach and the colon, skin lesions occur not only as eczema but also with a wide range of clinical and histological findings. In addition, multiple autoimmune disorders appear especially with increasing age. Finally, unlike IPEX syndrome, the IPEX-like disease has a slower progression and it is better controlled by IS therapy. Patients with CD25 deficiency represent an exception to this latter observation, since their clinical manifestations may be as severe and acute as in IPEX syndrome.

3.2. A quantitative defect of Treg cells is identified by TSDR demethylation analysis in IPEX-like patients {#sec3.2}
-----------------------------------------------------------------------------------------------------------

The amount of Treg cells in the peripheral blood was determined by TSDR demethylation analysis and it is expressed as percentage of nucleated cells. Results showed a median Treg cell amount of 0.67% in IPEX-like patients (*n* = 28; range from 0 to 2.83%) and of 1.40% in HS (*n* = 40; range from 0.56 to 3.42%) ([Fig. 1](#fig1){ref-type="fig"}A). These data indicate that, taken as a whole, IPEX-like patients have a significantly reduced percentage of peripheral Treg cells, as compared to HS (*p* \< 0.001). Importantly, analysis of the ROC curve showed an AUC of 0.90 (*p* \< 0.001). Considering a cut-off value of 1.07% Treg cells (the value minimizing the distance between the curve and the upper left corner of the graph), the test has a sensitivity of 96% and a specificity of 80%, thus supporting the observation that TSDR analysis discriminates IPEX-like patients from HS ([Fig. 1](#fig1){ref-type="fig"}B).

Since the absolute number of lymphocytes physiologically decreases with age [@bib33], we further analysed the amount of Treg cells across the different ages. Indeed, in pediatric HS (*n* = 27; ≤16 years of age; Treg range 0.56%--3.42%; median 1.48%) a significant age-dependent decrease of Treg cells was observed (Pearson correlation = −0.556, *p* = 0.003) ([Fig. 1](#fig1){ref-type="fig"}C). On the contrary, in pediatric IPEX-like patients, we did not observe any decrease in Treg cell amount in relation to age (*n* = 22; ≤16 years of age; Treg range 0%--2.83%; median 0.70%) ([Fig. 1](#fig1){ref-type="fig"}D). In adult IPEX-like patients (*n* = 6; \>16 years of age) and HS, Treg cell amount did not correlate with age (not shown), but the Treg percentage was confirmed to be consistently lower in patients (from 0.51% to 0.94%; median 0.60%) than in HS (from 0.72% to 3.25%; median 1.34%). Thus, in paediatric and adult IPEX-like patients, Treg cells are constantly reduced as compared to HS regardless of age.

3.3. Flow cytometric analysis may not detect a peripheral Treg cell defect {#sec3.3}
--------------------------------------------------------------------------

In 13/28 IPEX-like patients TSDR demethylation could be evaluated in parallel to the flow cytometric analysis for Treg cell quantification. Results showed that the percentages of FOXP3^+^ and CD25^+^FOXP3^+^ T cells, in gated CD4^+^ T cells, ranged from 0.3 to 18% (median = 3%) and from 0.3 to 17% (median = 2.5%), respectively ([Fig. 2](#fig2){ref-type="fig"}A, B; [Table 2](#tbl2){ref-type="table"}). In HS (*n* = 25), FOXP3^+^ T cells ranged from 2 to 8% (median = 5.7%) and CD25^+^FOXP3^+^ T cells from 1.2 to 6.6% (median = 4.3%) ([Fig. 2](#fig2){ref-type="fig"}A, B). Thus, according to flow cytometric analysis, median values obtained in IPEX-like patients were not significantly lower than those detected in HS (*p* = 0.207 for FOXP3^+^ T cells and *p* = 0.185 for CD25^+^FOXP3^+^ T cells). However, the former group had a highly variable amount of *FOXP3* expressing T cells, whereas HS displayed a more narrow distribution of FOXP3^+^ T cells ([Fig. 2](#fig2){ref-type="fig"}A, B). Addition of the negative Treg cell marker CD127 to the analysis did not reveal any significant difference in the size of the FOXP3^+^ T cell population of IPEX-like patients as compared to HS (data not shown). These results indicate that, despite the reduced Treg cell amount detected by TSDR analysis, the frequency of FOXP3 expressing cells measured by FACS analysis is not decreased in the peripheral blood of IPEX-like patients as compared to healthy donors. Analysis on a per-cell base (mean fluorescence intensity, MFI) revealed a weaker FOXP3 expression (in the CD4^+^FOXP3^+^ T cell gate) in patients as compared to HS (*p* = 0.039), suggestive of the presence of FOXP3^+^ activated Teff cells, rather than Treg cells, in which FOXP3 expression is stably high [@bib24]. CD25 MFI was not significantly different in patients and HS (*p* = 0.057) ([Fig. 2](#fig2){ref-type="fig"}C, D). Overall, these data highlight a discrepancy between results obtained by the TSDR demethylation analysis and the flow cytometric data. This discrepancy is mainly evident in patients with high frequency of FOXP3^+^ and CD25^+^FOXP3^+^ cells in the CD4^+^ T cell gate ([Table 2](#tbl2){ref-type="table"}). Thus, TSDR demethylation assay is more accurate than the flow cytometric analysis in the detection of peripheral Treg cells, especially when there is an overall increase of activated T cells.

3.4. Treg cell quantitative defect is confirmed by analysis of Treg cells within the CD3^+^ T cell compartment, as determined by TLSDR analysis {#sec3.4}
-----------------------------------------------------------------------------------------------------------------------------------------------

In order to clarify whether the Treg cell number measured by TSDR analysis could be influenced by the amount of CD3-expressing T cells, the Treg cell count was normalized to that of CD3^+^ cells, as determined by TLSDR demethylation assay. As shown by Pearson correlation analysis, both HS and IPEX-like patients showed a direct correlation between the total T cell and Treg cell percentage (Pearson correlation was 0.476 in patients, *p* = 0.010, and 0.617 in HS, *p* \< 0.001). However, Treg cells in IPEX-like patients did not maintain the same ratio to CD3-expressing T cells, as in HS ([Fig. 3](#fig3){ref-type="fig"}A). Robust regression analysis revealed two different patterns with slope 0.03 and 0.50 for patients and HS, respectively; *p*-value for the difference of the slopes was \<0.001 (1.27e-05).

In HS, CD3^+^ T cell distribution by TLSDR analysis ranged from 14.9% to 61.5% (median = 29.5%), whereas two groups of IPEX-like patients could be identified: one comprising lymphopenic patients (*n* = 11) with TLSDR \< 14.9% (i.e. the minimum value detected in HS), and a second group with TLSDR comparable to that of HS. The percentage of Treg cells within the CD3^+^ T cell population resulted highly variable in the group of lymphopenic patients (region (I), [Fig. 3](#fig3){ref-type="fig"}B), whereas it was more homogeneous in non-lymphopenic patients (*n* = 17, region (II), [Fig. 3](#fig3){ref-type="fig"}B). Overall, in the latter group a significant reduction of Treg cells could be detected ([Fig. 3](#fig3){ref-type="fig"}C), as compared to HS (Treg % in CD3^+^ T cells median and range were: 3.05 and 1.68--9.53 in IPEX-like; 4.89 and 1.87--10.78 in HS; *p* \< 0.001). We could not detect different distribution of patients with or without IS therapy (not shown). The same analysis performed in IPEX patients (*n* = 5), who are not lymphopenic, showed that Treg cells, although *FOXP3*-mutated, were present in higher amount than those detected in IPEX-like patients (Treg % in CD3^+^ T cells median and range: 9.84 and 6.79--20.79; *p* = 0.007) ([Fig. 3](#fig3){ref-type="fig"}C). As additional pathological controls we measured the percentage of Treg cells in CD3^+^ T cells in patients affected with diseases whose clinical features are also present in IPEX-like syndrome, but with clear different diagnosis, i.e. patients with T1DM (median and range: 4.53% and 3.43--6.90%, respectively), celiac disease (median and range: 4.32% and 3.12--6.44%, respectively) and Crohn's disease (median and range: 5.13% and 3.96--9.38%, respectively). In all three groups the frequency of Treg cells was not different from that detected in HS (T1DM: *p* = 0.522; celiac disease: *p* = 0.269; Crohn's disease: *p* = 0.492) and it was significantly higher as compared to IPEX-like patients (T1DM: *p* = 0.005;celiac disease: *p* = 0.026; Crohn's disease: *p* = 0.001).

Notably, statistical evaluation of the results obtained from HS and IPEX-like patients through the ROC curve, showed 80% probability to distinguish between IPEX-like patients and HS (AUC = 0.80, *p*\<0.001) based on the percentage of Treg/CD3 determined by TSDR and TLSDR analysis. Considering a cut-off value of 3.75% Treg cells in the T cell compartment, we obtained a sensitivity of 87%, a specificity of 65% (11 out of 17 patients showed a percentage of Treg cells below the cut-off), and an accuracy of 78% ([Fig. 3](#fig3){ref-type="fig"}D). Similarly, the TSDR/TLSDR assay showed 82% probability to distinguish IPEX-like patients from patients with different pathologies with overlapping symptoms (AUC = 0.82; [Supplementary Fig. 1](#appsec1){ref-type="sec"}). Thus, also the combined demethylation analysis of TSDR and TLSDR is a valid method allowing discrimination of IPEX-like patients from HS, patients with *FOXP3* mutations and patients with different autoimmune and autoinflammatory diseases.

3.5. Treg cells from IPEX-like patients display preserved suppressive function {#sec3.5}
------------------------------------------------------------------------------

In order to investigate whether Treg cells from IPEX-like patients retained suppressive function, CD4^+^CD25^+^ Treg cells were purified from the peripheral blood of four patients (patients \#15, 16, 17 and 20) and tested *in vitro* to evaluate their capacity to inhibit the proliferation of allogeneic and/or autologous responder cells ([Fig. 4](#fig4){ref-type="fig"}). Treg cells from all patients tested displayed preserved suppressive activity. With the exception of patient \#16, suppressive activity was comparable to that of control Treg cells tested in parallel versus both CD4^+^ and CD8^+^ T cells from HS, used as responder cells (*n* = 3) (*p* \> 0.05, Wilcoxon signed rank test). Inhibitory capacity was also maintained when patients' PBMC were used as responder cells (*n* = 3, for patients' CD4^+^ responder cells and *n* = 2 for patients CD8^+^ responder cells) ([Fig. 4](#fig4){ref-type="fig"}A and B). Further functional characterization of patients' Treg cells revealed that, similar to those of HS, CD4^+^CD25^+^ T cells from patients were hypoproliferative (not shown). These results indicate that Treg cell suppressive function in patients with IPEX-like syndrome is fully preserved.

4. Discussion {#sec4}
=============

IPEX-like syndrome is a heterogeneous nosological entity that remains mostly of unknown origin, although specific primary immunodeficiencies can be distinguished therein, such as genetic defects in *CD25* [@bib7; @bib15]. In the present study, we examined a cohort of 28 patients with clinical features resembling IPEX syndrome in the absence of *FOXP3* mutations. We show that the large majority of these IPEX-like patients have low frequency of peripheral Treg cells, detected with high sensitivity and specificity by TSDR demethylation assay. Thus, we provide evidence that a quantitative defect of Treg cells can be considered a biological hallmark of IPEX-like syndrome.

For the first time, we describe a large cohort of patients presenting with IPEX-like syndrome, in which, similarly to IPEX, autoimmune enteropathy is the most frequent clinical feature together with skin lesions and other autoimmune manifestations, such as T1DM. However, unlike in IPEX, in IPEX-like syndrome the enteropathy has a variable age of onset and also females can be affected. Skin involvement is mostly characterized by eczematous lesions, although a wide spectrum of skin pathologies can be observed. Other autoimmune symptoms comprise thyroiditis, cytopenias, hepatitis, cholangitis, atrophic gastritis, and ankylosing spondylitis. Immunological disorders such as IgA deficiency, hypogammaglobulinemia, and increased serum IgE levels can be present, together with high eosinophil counts. Despite several clinical similarities with IPEX syndrome, which justify the general definition as IPEX-like, the course of the disease is less severe and patients show better therapy response.

In the attempt to investigate the pathogenesis of the disease, we and others have questioned whether the Treg compartment is affected as in IPEX syndrome. Previous studies, using flow cytometric analysis led to insufficient results to support the hypothesis of a Treg cell reduction [@bib8; @bib9]. These data include an evaluation of Treg cells, previously performed in five IPEX-like patients (all under IS therapy), among whom, three were diagnosed with low CD25^+^CD127^dim^FOXP3^+^ T cell counts, and two others had a normal proportion of these cells [@bib8; @bib9].

In the present cohort of IPEX-like patients, using the highly Treg-specific TSDR demethylation assay [@bib34], we were able to identify a consistent quantitative deficiency of Treg cells. The defect could not be detected by flow cytometry that showed, on the contrary, variable results. The discrepancy between demethylation and flow cytometric analysis was particularly evident in patients with the highest number of CD4^+^FOXP3^+^ T cells (patient \#9 and \#21, who had a low amount of TSDR-demethylated cells). These data suggest that, in the presence of activated Teff cells, transiently expressing CD25 and FOXP3 [@bib24; @bib35], flow cytometric analysis loses specificity to quantify peripheral *bona fide* Treg cells. This limitation is more likely to occur in patients with ongoing autoimmunity and, therefore, high amount of circulating activated T cells. Thus, especially in these conditions, TSDR demethylation analysis emerges as a key complementary method to evaluate *bona fide* Treg cell amount. Moreover, the combined analysis of TSDR and TLSDR demethylation allows quantification of Treg cells within the total amount of T cells, so that Treg cells can be studied in lymphopenic and non-lymphopenic patients. Indeed, in non-lymphopenic IPEX-like patients, the low number of Treg cells was confirmed, suggesting that autoimmunity could be sustained by an unbalanced Treg/T cell ratio, with consequent insufficient amount of Treg cells to control pathogenic Teff cells. Furthermore, our results demonstrate that the Treg cell reduction is a feature specific for patients with IPEX-like syndrome, since it is not detected in patients with other autoimmune pathologies of different origin. On the contrary, a different aetiology of the autoimmunity can be hypothesized in lymphopenic patients, in whom the reduction of Treg cells is associated with an overall decreased amount of CD3^+^ T cells.

Statistical evaluation of results through the ROC curve showed that both methods have high probability to discriminate between IPEX-like patients and HS: 90% (AUC = 0.90) considering the TSDR demethylation analysis alone, and 80% (AUC = 0.80) using the combined TSDR/TLSDR demethylation analysis. The latter assays also allow the distinction between IPEX-like patients and other pathologic controls (AUC = 0.82). Hence, parallel demethylation analysis of TSDR and TLSDR identifies a biological parameter, alternative or complementary to flow cytometry, which permits precise Treg cell quantification and exclusion of concomitant lymphopenia, often characterizing primary immunodeficiencies. In addition, demethylation analysis can be performed with low amount of biological material (i.e. less than 200 μL of peripheral blood), allowing highly reproducible quantification of Treg cells even in infants, in whom blood sampling is limited.

Despite reduced in number, Treg cells of IPEX-like patients displayed preserved suppressive function in all patients tested. Previous studies reported that Treg cell in vitro function in patients with autoimmune enteropathy, without *FOXP3* mutations could vary from normal to reduced in relationship with the level of FOXP3 expression [@bib8; @bib9]. Interestingly, all the patients that we tested had low frequency of Treg cells as measured by TSDR assay. When the percentage of Treg cells was normalized by TLSDR, only in two out of four patients (patients \#15 and 20), both with fully preserved *in vitro* suppressive activity, the Treg cell frequency was below the cut-off value, thus suggesting that in these patients autoimmunity may indeed be due to reduced Treg cell frequency. In one patient (patient \#16) the overall low Treg cell number was due to presence of lymphopenia, as demonstrated by TLSDR assay. In this case the quantitative assay is not informative, since Treg cells were not specifically undersized with regard to the Teff cell compartment. In addition, their function resulted partially defective, thus leaving the possibility that in this patient the pathology could be due to a complex defect including the functional impairment of Treg cells alone or rather of multiple T cell subsets. In the last patient tested (patient \#17) both Treg cell number and function were comparable to healthy subjects, thus indicating that the defect underlying the disease is likely to affect the effector rather than the regulatory T cell compartment, as also indicated by the partial resistance to suppression of patient's responder cells. Overall, our functional results still confirm a certain heterogeneity within IPEX-like patients, although clearly identifies a cohort in which the quantitative Treg defect is present. Our approach allows the rapid and precise identification of this subgroup of patients, who would potentially benefit from innovative therapies based on the adoptive transfer of *ex-vivo* expanded autologous Treg cells.

The reduction of Treg cells has been observed in other autoimmune diseases [@bib36; @bib37], but the causes of this reduction still need to be clarified. The unbalance between the Treg/Teff compartments may be due either to defective homeostatic proliferation of the peripheral Treg cell pool as compared to the conventional T cell pool, or to impairment of peripheral Treg cell survival. Alternatively, Treg cells may be reduced due to impaired thymic development and/or migration to periphery. Further studies on patients affected with IPEX-like syndrome are required to identify the biological/molecular cause of the Treg cell decrease.

Overall, we propose TSDR and TLSDR demethylation analysis as reliable tools for the quantitative evaluation of Treg cells in patients with immune dysregulation, allowing the identification of a defect otherwise not detectable in IPEX-like patients, integrating flow cytometric evaluation, especially in the presence of inflammation, and standardizing the quantification of Treg cells. Our analysis provides new insights into the pathogenesis of at least a subset of IPEX-like patients, in whom autoimmunity can be ascribed to the unbalance between the Treg/Teff compartments, thus paving the way for the development of targeted therapies.

Disclosure statement {#sec5}
====================

S.O. has declared a financial interest in a Company whose potential product was used in the present work. All other authors have no conflicting financial interests.

Appendix. Supplementary data {#appsec1}
============================

This work was supported by the Italian Telethon foundation (Grant Tele10A4 and GGP07241 to R.B.), by the Seventh framework programme (FP7) of the European Community for research, technological development and demonstration activities (Cell-PID to R.B.), and by the Italian Ministry of Health (Grant RF-2009-1485896 to R.B.). The Authors are grateful to Prof. G.R. Corazza, Clinica Medica I, Fondazione IRCCS Policlinico San Matteo, Università degli Studi di Pavia, Italy, for his clinical expertise. The Authors also thank M. Battaglia, G. Giamporcaro and A. Valle from the Diabetes Research Institute, San Raffaele Scientific Institute, Milan, Italy for help in collecting samples from diabetic patients.

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.jaut.2011.12.009](10.1016/j.jaut.2011.12.009).

![TSDR demethylation analysis in the peripheral blood of IPEX-like patients. (A) Comparison between median Treg percentages (measured by TSDR demethylation assay), in the peripheral blood of HS (white bar, *n* = 40) and IPEX-like patients (grey bar, *n* = 28). Middle line indicates the median. The box represents 50% of all events and the whiskers extend to 95%. Statistical analysis was performed with Mann--Whitney *U*-test. (B) ROC curve describing the performance of TSDR assay in discriminating patients and HS. AUC value reflecting the discrimination between groups is indicated. (C, D) Scatter plot and linear regression between the percentage of Treg cells and age in healthy paediatric controls (*n* = 27), and IPEX-like paediatric patients (*n* = 22), all under 16 years.](gr1){#fig1}

![Flow cytometric analysis of Treg cells in the peripheral blood of IPEX-like patients. *FOXP3*^+^ cells were detected by flow cytometry in the peripheral blood of IPEX-like patients (*n* = 13) and HS (*n* = 25). Percentage of FOXP3^+^ T cells in the (A) CD4^+^ and (B) CD4^+^CD25^+^ T cell gates are plotted in the graphs. Mean fluorescence intensity of marker expression in (C) CD4^+^FOXP3^+^ and (D) CD4^+^CD25^+^ T cells is also shown. Differences between groups were verified by means of Mann--Whitney *U*-test.](gr2){#fig2}

![Treg cell normalization to CD3^+^ T cell counts. (A) Robust regression plots of the % of Treg cells vs the % of CD3-expressing cells (as measured by TSDR and TLSDR assays) in the peripheral blood of HS (left panel) and IPEX-like patients (right panel) are shown. Pearson correlation values were 0.617 (*p* \< 0.001) for HS and 0.476 (*p* = 0.010) for patients. (B) The percentage of Treg cells normalized to TLSDR was plotted versus the CD3^+^ cell counts, as measured by TLSDR assay. Region (I) comprises lymphopenic patients, in whom the % of CD3-expressing cells in whole blood was below 14.9%; region (II) identifies patients with lymphocyte cell counts within normal ranges. (C) The box-plots show the % of Treg normalized to CD3^+^ T cell amount (as measured by TSDR and TLSDR combined analysis) in HS (white bar) and non-lymphopenic IPEX-like (light grey) and control patients (dark grey). Control pathologies include: IPEX syndrome (*n* = 5), T1DM (*n* = 10), Celiac (*n* = 9) and Crohn (*n* = 8) diseases. Middle lines represent the median. Statistical analysis was performed with Mann--Whitney *U*-test, *p* \< 0.05 was considered significant. (D) The ROC curve describes the performance of the combined TSDR/TLSDR assays in discriminating HS and IPEX-like patients. AUC value reflecting the discrimination between groups is indicated.](gr3){#fig3}

![Suppressive function of Treg cells isolated from the peripheral blood of IPEX-like patients. CD4^+^CD25^+^ T cells isolated from the peripheral blood of IPEX-like patients were used as suppressor cells in a suppression assay, using allogeneic and/or autologous PBMC as responders. CD4^+^CD25^+^ T cells isolated from the peripheral blood of one HS were tested in parallel and used as control. (A) Histograms of CFSE dilution of one representative patient (\#20) are shown. Analysis was performed by gating either on CD4^+^ or on CD8^+^ responder T cells. Numbers in the plots indicate percent inhibition. The relative \[suppressor: PBMC responder\] cell ratio is also indicated. (B) Average %inhibition of proliferation versus the indicated responder cells is plotted in the graphs. The highest \[suppressor: responder\] cell ratio tested is plotted for each patient. Black symbols refer to patients, white symbols to HS tested in parallel. ●: Patient \#20; ▲: Patient \#17; ■: Patient \#15; ♦: Patient \#16.](gr4){#fig4}

###### 

Clinical findings in the cohort study of IPEX-like patients.

  \#                                     Age     Onset      GI symptoms                                   Endocrinopathy      Skin                                              Infections                                                                Other                                                                                               Therapy                        L
  -------------------------------------- ------- ---------- --------------------------------------------- ------------------- ------------------------------------------------- ------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------ ---
  1[a](#tbl1fna){ref-type="table-fn"}    5y      1m         Enteropathy, VA                               Thyroiditis         Psoriasiform dermatitis, Alopecia universalis     Chronic CMV infection                                                     No                                                                                                  FK506                          ↓
  2                                      3y 7m   2y         Enteropathy                                   No                  No                                                No                                                                        Nephropathy, Thrombosis                                                                             PD, AZA                        ↓
  3                                      2y      5m         Enteropathy, VA, Vomiting                     No                  No                                                Sepsis                                                                    Hypothyroidism (uncertain origin)                                                                   PN                             N
  4                                      10y     na         Enteropathy                                   No                  Erythrodermia                                     No                                                                        Nephrotic syndrome                                                                                  AZA                            N
  5                                      2m      2m         Enteropathy, Vomiting                         No                  No                                                No                                                                        Eosinophilia                                                                                        TPN                            N
  6                                      18y     2y         Enteropathy, VA                               T1DM                Esfoliative dermatitis, Alopecia, fragile nails   Sepsis                                                                    Glomerulonephritis, Thrombocytopenia, AHA, A. hepatitis, Vasculitis                                 Steroids, FK506                ↓
  7                                      4y      6m         Enteropathy                                   T1DM                Eczema                                            No                                                                        No                                                                                                  No                             ↓
  8                                      4m      2m         Enteropathy                                   No                  No                                                No                                                                        No                                                                                                  IS                             ↓
  9                                      3m      2m         Enteropathy                                   Thyroiditis         Eczema                                            Sepsis                                                                    Abnormal CNS seizures, Abnormal EEG findings                                                        Ig IV                          ↓
  10                                     3m      2m         Enteropathy, VA                               No                  No                                                No                                                                        No                                                                                                  MPD, CS                        N
  11                                     16y     7y         Intermittent enteropathy                      No                  Nodular eritema                                   RRI                                                                       Chronic nephritis                                                                                   Steroids, AZA                  ↓
  12                                     7y      4m         Enteropathy                                   No                  Bullous pemphigoid                                No                                                                        AHA, A. hepatitis, arthritis                                                                        Steroids, Rituximab, MMF, Cx   ↓
  13                                     5y      5m         Enteropathy, Vomiting                         T1DM                Vitiligo                                          No                                                                        No                                                                                                  Past steroids, TPN             N
  14                                     20y     Neonatal   Enteropathy                                   No                  Mild eczema                                       RRI                                                                       A. hepatitis, Failure to thrive                                                                     FK506                          N
  15                                     1y 9m   9m         Enteropathy                                   Thyroiditis         Atopic dermatitis                                 CMV colitis, Otitis, pneumonia                                            No                                                                                                  PD, AZA                        N
  16                                     2m      Neonatal   Enteropathy                                   No                  No                                                No                                                                        No                                                                                                  MPD                            ↓
  17                                     10y     6y         Ulcerative colitis                            T1DM                Urticaria-like                                    Recurrent otitis, Tonsillitis                                             Hypogammaglobulinemia, Partial IgAD                                                                 5-ASA                          N
  18                                     2y 5m   1y         No                                            T1DM                Eczema, Alopecia                                  No                                                                        Growth retardation, Hyper IgE                                                                       No                             N
  19                                     38y     19y        Enteropathy                                   T1DM, thyroiditis   Psoriasis                                         Recurrent foruncolosis                                                    IgAD, AAG, AT                                                                                       PD                             N
  20                                     34y     10y        Enteropathy                                   No                  Vitiligo, Alopecia                                Recurrent infections (upper airways, sinusitis, pneumonias, meningitis)   Hypogammaglobulinemia, AAG                                                                          Ig IV                          N
  21                                     33y     17y        Ulcerative colitis                            No                  Parapsoriasis                                     No                                                                        Ankylosing spondylitis, A. colangytis, interstitial pneumonia, hyper IgE                            PD                             N
  22[a](#tbl1fna){ref-type="table-fn"}   4m      20d        Enteropathy                                   T1DM, Thyroiditis   Mild eczema                                       CMV infection, Pneumonia                                                  AHA, lymphadenopathy, CNS bleeding, Axial hypotonia, Failure to thrive, Hyper IgE, Hyper IgG, IgA   Ig IV                          N
  23                                     1y 5m   6m         Enteropathy, VA, Gastric and colonic ulcers   No                  No                                                No                                                                        Hyper IgE, Eosinophilia, Food allergy                                                               MPD                            N

GI: gastrointestinal; VA: villous atrophy; T1DM: Type 1 diabetes mellitus; CMV: cytomegalovirus; RRI: recurrent respiratory infections; A: autoimmune; CNS: central nervous system; AHA: autoimmune haemolytic anemia; IgAD: IgA deficiency; AAG: autoimmune atrophic gastritis; AT: autoimmune thrombocytopenia; FK506: tacrolimus; PD: prednisone; AZA: azathioprine; PN: parenteral nutrition; TPN: total parenteral nutrition; IS: immunosuppressive drugs; IV: intravenous; MPD: methylprednisone; CS: corticosteroid; MMF: mycophenolate mophetyl; Cx: cyclophosphamide; 5-ASA: mesalazine; L: lymphocytes count; na: not available; N: normal.

Patient with *CD25* mutation.

###### 

Parallel evaluation of Treg cell counts by TSDR demethylation analysis, FOXP3^+^ and FOXP3^+^CD25^+^ T cells percentage by flow cytometric analysis and MFI in IPEX-like patients.

  \#   Treg (%)   FOXP3^+^ cells (% in CD4^+^ gate)   FOXP3 MFI   CD25^+^FOXP3^+^ cells (% in CD4^+^ gate)   CD25 MFI
  ---- ---------- ----------------------------------- ----------- ------------------------------------------ ----------
  5    0.89       8.36                                568         5.21                                       na
  9    0.89       18.19                               413         17.05                                      1569
  10   0.95       5.58                                391         5.14                                       754
  11   0          3.58                                259         2.75                                       850
  13   1.04       13.75                               553         8.81                                       451
  16   0.56       1.88                                422         1.59                                       1334
  17   0.83       2.70                                440         1.92                                       2292
  18   0.91       3.09                                763         2.53                                       587
  19   0.54       2.90                                493         2.15                                       1879
  20   0.67       2.26                                390         2.01                                       848
  21   0.94       9.70                                1017        9.25                                       1185
  22   0.67       2.45                                550         1.45                                       759
  23   0.74       0.35                                476         0.35                                       610

na: not available.
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